Laudanum Uniform Controlled Substances Act, which regulated opium tincture (Laudanum) as a Schedule II substance (currently DEA #9630), placing even tighter controls on the drug. By the late 20th century, laudanum's use was almost exclusively confined to treating severe diarrhea. The current prescribing information for laudanum in the US states that opium tincture's sole indication is as an anti-diarrheal, although the drug is occasionally prescribed off-label for treating pain and neonatal withdrawal syndrome. Several historical varieties of laudanum exist, including Paracelsus' laudanum, Sydenham's Laudanum (also known as "tinctura opii crocata"), benzoic laudanum ("tinctura opii benzoica"), and deodorized tincture of opium (the
Drug Houses of Australia Drug Houses of Australia Drug Houses of Australia (DHA) was originally established in 1936 as an amalgamation of seven Australian pharmaceutical companies, notably A. M. Bickford & Sons. In 1970, DHA was taken over by the British bank Slater Walker. Drug Houses of Australia is now a leading generic pharmaceutics and Chinese proprietary medicine (CPM) manufacturer based in Jurong, Singapore. It was sold to Strides Arcolab through a share purchase agreement with Haw Par Healthcare Limited, Singapore in September 2006 for approximately SGD$19.7 million. It is currently a part of Strides Arcolab which is listed on both the Indian stock